KineMed, Inc. has announced that it has signed an exclusive agreement with Forbes Medi-Tech Inc. to discover non-cardiovascular indications for an undisclosed compound in the Forbes library of small molecule compounds.
Under the terms of the agreement, KineMed will screen the Forbes compound using KineMed's proprietary in vivo KineMarker™ assays.
KineMed and Forbes will have the option to pursue development of the compound in any discovered indications.
"We are excited to collaborate with Forbes and expect to begin evaluating additional therapeutic activity this quarter," said David Fineman, President and CEO of KineMed.
"Our goal is to identify potential applications that can address large markets with substantial unmet medical needs."
"This collaboration represents KineMed's continued progress in the application of our KineMarker platform to new indications discovery."